stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Revenue
Exelixis, Inc.'s revenue for fiscal 2025 was $2.3B, up 6.98% from $2.2B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.5B. Over the past ten years it has ranged from $37.2M (fiscal 2015) to $2.3B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. Exelixis, Inc. ranks 13th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.3B | 6.98% |
| FY2024 | $2.2B | 18.49% |
| FY2023 | $1.8B | 13.60% |
| FY2022 | $1.6B | 12.27% |
| FY2021 | $1.4B | 45.31% |
| FY2020 | $987.5M | 2.04% |
| FY2019 | $967.8M | 13.35% |
| FY2018 | $853.8M | 88.70% |
| FY2017 | $452.5M | 136.34% |
| FY2016 | $191.5M | 415.05% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $658.7M | 4.77% |
| Jun 2026 | $628.7M | 2.93% |
| Mar 2026 | $610.8M | 2.03% |
| Dec 2025 | $598.7M | 0.15% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $5.0B |
| JAZZ Jazz Pharmaceuticals PLC compare | $4.7B |
| BNTX BioNTech SE Sponsored ADR compare | $2.7B |
| EXEL Exelixis, Inc. | $2.5B |
| HALO Halozyme Therapeutics, Inc. compare | $1.8B |
| INSM Insmed, Inc. compare | $1.5B |
| ASND Ascendis Pharma A/S compare | $1.2B |
| BBIO BridgeBio Pharma, Inc. compare | $945.5M |
| SMMT Summit Therapeutics PLC compare | $705.0K |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on EXEL
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement